A phase II study to determine the ability of gefitinib to reverse fluoropyrimidine resistance in metastatic colorectal cancer (the INFORM study)

There are data suggesting that inhibition of epidermal growth factor receptor (EGFR) tyrosine kinase signalling may reverse resistance to fluoropyrimidine treatment. To investigate this further, the INFORM study was an open-label, non-comparative phase II study of gefitinib (Iressa, ZD1839; AstraZen...

Descripción completa

Detalles Bibliográficos
Autores principales: Stebbing, J, Harrison, M, Glynne-Jones, R, Bridgewater, J, Propper, D
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2259185/
https://www.ncbi.nlm.nih.gov/pubmed/18253119
http://dx.doi.org/10.1038/sj.bjc.6604232

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2259185/
https://www.ncbi.nlm.nih.gov/pubmed/18253119
http://dx.doi.org/10.1038/sj.bjc.6604232

Ejemplares similares